Amin Reshma, Noone Peadar G, Ratjen Felix
Department of Pediatric Respirology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada, M5G 1X8.
Cochrane Database Syst Rev. 2009 Apr 15(2):CD007481. doi: 10.1002/14651858.CD007481.pub2.
Pneumothorax is a potentially life-threatening complication for people with cystic fibrosis. Spontaneous pneumothorax is the presence of air in the pleural space and can be subdivided into first episode and recurrent. The recurrence of pneumothorax is when it occurs on the same side seven days or more after initial resolution. A pneumothorax is persistent if the air leak lasts for more than five days (Schidlow 1993). Managing spontaneous pneumothoraces is controversial and there is no standard treatment. Medical and surgical intervention are the two main categories for the treatment of recurrent pneumothoraces in people with cystic fibrosis. While surgical interventions are felt to be more effective in people without cystic fibrosis, the complications directly related to the procedure, as well as the post-operative complications make surgical interventions riskier for people with cystic fibrosis. Additionally, these interventions have the potential to make people with cystic fibrosis ineligible for lung transplantation in the future. Therefore, the benefits and side effects or disadvantages for the medical and surgical treatment of recurrent pneumothoraces in people with cystic fibrosis need to be systematically reviewed.
To determine the clinical efficacy and safety of different treatment interventions for managing spontaneous persistent and recurrent pneumothoraces in people with cystic fibrosis.
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings.Date of the most recent search: 19 August 2008.
Randomised and quasi-randomised controlled trials which compared the use of chemical pleurodesis to surgical interventions for the treatment of persistent and recurrent pneumothoraces in CF.
No relevant trials were identified.
No trials were included in this review
AUTHORS' CONCLUSIONS: Pneumothorax is a potentially life-threatening complication for people with cystic fibrosis and the management of spontaneous pneumothoraces remains a topic of considerable controversy. Medical and surgical intervention are the two main categories for the treatment of recurrent pneumothoraces in this population. However, it is disappointing that neither intervention has been assessed by randomised controlled trials. This systematic review identifies the need for a multicentre randomised controlled trial assessing both efficacy and possible adverse effects of the use of chemical pleurodesis versus surgical interventions for the treatment of persistent and recurrent pneumothoraces in people with cystic fibrosis.
气胸是囊性纤维化患者潜在的危及生命的并发症。自发性气胸是指胸膜腔内存在气体,可分为首次发作和复发性。气胸复发是指在初次缓解后7天或更长时间在同一侧再次发生。如果漏气持续超过5天,则气胸为持续性(施德洛,1993年)。自发性气胸的管理存在争议,且没有标准的治疗方法。医学和外科干预是治疗囊性纤维化患者复发性气胸的两大类。虽然外科干预在非囊性纤维化患者中被认为更有效,但与手术直接相关的并发症以及术后并发症使外科干预对囊性纤维化患者风险更高。此外,这些干预措施有可能使囊性纤维化患者未来无资格接受肺移植。因此,需要系统评价囊性纤维化患者复发性气胸的医学和外科治疗的益处及副作用或不利之处。
确定不同治疗干预措施治疗囊性纤维化患者自发性持续性和复发性气胸的临床疗效和安全性。
我们检索了Cochrane囊性纤维化和遗传疾病小组试验注册库,该注册库包括从全面电子数据库检索、相关期刊手工检索和会议论文摘要集中识别的参考文献。最近一次检索日期:2008年8月19日。
比较化学性胸膜固定术与外科干预治疗囊性纤维化患者持续性和复发性气胸的随机和半随机对照试验。
未识别出相关试验。
本综述未纳入试验。
气胸是囊性纤维化患者潜在的危及生命的并发症,自发性气胸的管理仍然是一个有相当争议的话题。医学和外科干预是该人群复发性气胸治疗的两大类。然而,令人失望的是,这两种干预措施均未通过随机对照试验进行评估。本系统评价表明,需要进行一项多中心随机对照试验,评估化学性胸膜固定术与外科干预治疗囊性纤维化患者持续性和复发性气胸的疗效及可能的不良反应。